Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tamsulosin Hydrochloride

FDA-approved product (capsule, oral), marketed as Flomax, Tamsulosin Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tamsulosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis73.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tamsulosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tamsulosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia

    NCT02034604 · start 2013-12

    Registered record
    Registry ID
    NCT02034604
    Conditions
    Neurogenic Lower Urinary Tract Dysfunction
    Interventions
    Naftofidil; Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-12
    Completion
    2017-08
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurogenic Lower Urinary Tract Dysfunction
    InterventionNaftofidil; Tamsulosin
    PhasePhase 4
    Registry statusCompleted

  • This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples

    NCT01957189 · start 2013-10-25

    Registered record
    Registry ID
    NCT01957189
    Conditions
    Prostatic Hyperplasia
    Interventions
    Dutasteride and Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10-25
    Completion
    2014-01-22
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionDutasteride and Tamsulosin
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

    NCT02003742 · start 2013-09

    Registered record
    Registry ID
    NCT02003742
    Conditions
    Lower Urinary Tract Symptoms
    Interventions
    NX-1207; Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-09
    Completion
    2015-01-29
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLower Urinary Tract Symptoms
    InterventionNX-1207; Tamsulosin
    PhasePhase 3
    Registry statusTerminated

  • JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

    NCT01830829 · start 2013-04

    Registered record
    Registry ID
    NCT01830829
    Conditions
    Benign Prostatic Hyperplasia; Chronic Prostatitis
    Interventions
    Jalyn; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-04
    Completion
    2014-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Chronic Prostatitis
    InterventionJalyn; Placebo
    PhasePhase 3
    Registry statusTerminated

  • PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination

    NCT01829893 · start 2012-01

    Registered record
    Registry ID
    NCT01829893
    Conditions
    Benign Prostatic Hyperplasia (BPH)
    Interventions
    In combination of 0.2mg finasteride and 5mg tamsulosin; GL2701 capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-02
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia (BPH)
    InterventionIn combination of 0.2mg finasteride and 5mg tamsulosin; GL2701 capsule
    PhasePhase 1
    Registry statusCompleted

  • Orthostatic Hypotension Treatment on Rehab Unit

    NCT01030874 · start 2011-10

    Registered record
    Registry ID
    NCT01030874
    Conditions
    Orthostatic Hypotension; Falls
    Interventions
    Medication review; Nutrition/Salt intake; Education; Exercise; Drug Recommendations
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-10
    Completion
    2016-05
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOrthostatic Hypotension; Falls
    InterventionMedication review; Nutrition/Salt intake; Education; Exercise +1 more
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.

    NCT01254071 · start 2010-09-10

    Registered record
    Registry ID
    NCT01254071
    Conditions
    Prostatic Hyperplasia
    Interventions
    Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-09-10
    Completion
    2010-12-21
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionDutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
    PhasePhase 1
    Registry statusCompleted

  • Combined Behavioral and Drug Treatment of Overactive Bladder in Men

    NCT01175382 · start 2010-07

    Registered record
    Registry ID
    NCT01175382
    Conditions
    Overactive Bladder; Lower Urinary Tract Symptoms
    Interventions
    Behavioral training; Tolterodine + tamsulosin; Combined Behavioral + Drug Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-07
    Completion
    2015-07
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder; Lower Urinary Tract Symptoms
    InterventionBehavioral training; Tolterodine + tamsulosin; Combined Behavioral + Drug Therapy
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

    NCT01953887 · start 2010-03

    Registered record
    Registry ID
    NCT01953887
    Conditions
    EC905; Pharmacokinetics; Healthy Subjects
    Interventions
    EC905; solifenacin; tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEC905; Pharmacokinetics; Healthy Subjects
    InterventionEC905; solifenacin; tamsulosin
    PhasePhase 1
    Registry statusCompleted

  • Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis

    NCT00913315 · start 2009-08

    Registered record
    Registry ID
    NCT00913315
    Conditions
    Prostatitis
    Interventions
    tolterodine; tamsulosin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2009-08
    Completion
    2010-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatitis
    Interventiontolterodine; tamsulosin; placebo
    PhaseNot applicable
    Registry statusUnknown

  • Corneal Endothelium Cell Loss After Cataract Extraction in Patients Taking Tamsulosin

    NCT01076309 · start 2009-06

    Registered record
    Registry ID
    NCT01076309
    Conditions
    Cataract
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-06
    Completion
    2010-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

    NCT02264184 · start 2008-09

    Registered record
    Registry ID
    NCT02264184
    Conditions
    Healthy
    Interventions
    Tamsulosin; Paroxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTamsulosin; Paroxetine
    PhasePhase 1
    Registry statusCompleted

  • Tamsulosin and the Risk of Serious Adverse Events

    NCT07274228 · start 2008-01-01

    Registered record
    Registry ID
    NCT07274228
    Conditions
    Chronic Kidney Disease (CKD)
    Interventions
    Tamsulosin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2008-01-01
    Completion
    2027-12-31
    Enrolment
    14,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease (CKD)
    InterventionTamsulosin
    PhaseNot recorded
    Registry statusActive not recruiting

  • The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones

    NCT00451061 · start 2007-04

    Registered record
    Registry ID
    NCT00451061
    Conditions
    Renal Colic
    Interventions
    Alfuzosin; Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-04
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Colic
    InterventionAlfuzosin; Tamsulosin
    PhasePhase 4
    Registry statusUnknown

  • Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

    NCT02245555 · start 2006-04

    Registered record
    Registry ID
    NCT02245555
    Conditions
    Prostatic Hyperplasia
    Interventions
    Tamsulosin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-04
    Completion
    Not recorded
    Enrolment
    1,060

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionTamsulosin
    PhaseNot recorded
    Registry statusCompleted